



Application of the Chinese Visceral Adiposity Index in the Diagnosis of Hepatic Steatosis and Liver Fibrosis: A Cross-Sectional Study

Ayoub Basham ¹, Shideh Rafati ², Saeed Hosseini Teshnizi ³, Ebrahim Evazi ¹, Fereshteh Khozimeh ⁴, Seyed Moayed Alavian ⁵, Farkhondeh Razmpour ⁶,*

¹ Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

² Social Determinants in Health Promotion Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

³ Department of Community Medicine, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

⁴ Department of Nutrition Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

⁵ Internal Medicine Research Center, Middle East Liver Disease Center, Tehran, Iran

⁶ Department of Nutrition, Faculty of Medicine, Hormozghan University of Medical Sciences, Bandar Abbas, Iran

*Corresponding Author: Department of Nutrition, Faculty of Medicine, Hormozghan University of Medical Sciences, Bandar Abbas, Iran Email: frazmpoor@gmail.com

Received: 29 June, 2024; Revised: 14 October, 2024; Accepted: 17 October, 2024

Abstract

Background: Visceral fat exerts a significant impact on the histopathology of metabolic dysfunction-associated steatotic liver disease (MASLD). Hence, we evaluated the application of the Chinese Visceral Adiposity Index (CVAI), a novel visceral fat marker, in predicting and diagnosing hepatic steatosis and liver fibrosis.

Methods: After excluding individuals with liver disease or significant alcohol consumption, a total of 273 patients (57.9% males) aged over 18 were eligible for this cross-sectional study. Chinese Visceral Adiposity Index was calculated by age, Body Mass Index (BMI), waist circumference (WC), triglyceride, and high-density lipoprotein cholesterol (HDL-C). Hepatic steatosis and fibrosis were measured by elastography. A P-value of less than 0.05 was considered significant.

Results: After adjusting for age, gender, metabolic diseases, and visceral obesity indices, each unit increase in CVAI elevated the odds of hepatic steatosis and liver fibrosis by 3.3% ($P = 0.002$) and 2.9% ($P = 0.001$), respectively. According to the analysis of variance (ANOVA), the grades of liver steatosis had a great impact on CVAI ($P < 0.001$), and CVAI well-discriminated grades of liver steatosis. Furthermore, the stages of liver fibrosis greatly impacted CVAI ($P < 0.001$), but it cannot distinguish the stages of liver fibrosis. The Area Under the Receiver Operating Characteristic Curve (AUROC) for $S \geq S1$ was 0.800 (0.747 to 0.846), and for $F \geq F2$ was 0.810 (0.759 to 0.855).

Conclusions: We concluded that CVAI is a strong predictor and accurate diagnostic factor for liver steatosis and significant fibrosis; thus, it could be a tool for screening individuals at risk of liver steatosis and the irreversible complications of fibrosis.

Keywords: Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, Non-alcoholic Fatty Liver Disease, NAFLD, Lipid Accumulation Product, Visceral Adiposity Index

1. Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a comprehensive term that refers to hepatic steatosis associated with obesity or overweight, diabetes mellitus, or the presence of at least two metabolic abnormalities. These abnormalities include increased waist circumference (WC), hypertension, prediabetes, hypertriglyceridemia, and reduced levels of high-density lipoprotein cholesterol (HDL-C) (1). Hepatic

steatosis may induce hepatic inflammation and fibrogenesis, which can advance to liver cirrhosis, liver failure, and hepatocellular carcinoma (2). In the last few decades, rapid changes in lifestyles and dietary habits increased the prevalence of MASLD to 32.4% worldwide and 33% in Iran (3, 4). However, the health system still lacks a screening program to detect individuals at risk of MASLD and related complications (5). Liver biopsy is still the gold standard for the diagnosis of liver steatosis and fibrosis, but non-invasive techniques are commonly

used for diagnostic purposes in clinical settings (6). Transient elastography (TE) is an accurate alternative to liver biopsy for diagnosing and grading hepatic steatosis and fibrosis (6, 7). However, the expenses of its use restrict its application in research settings.

Several factors contribute to the development and progression of MASLD, including physical inactivity, obesity, visceral adipose tissue (VAT), insulin resistance, dyslipidemia, and liver inflammation (8-10). Visceral fat, compared to subcutaneous fat, plays a significant role in the development and progression of MASLD (11). Computed tomography (CT) and Magnetic Resonance imaging (MRI) are valuable tools for assessing fat distribution and measuring VAT. However, their high costs, time consumption, and potential radiation exposure present significant drawbacks. As a result, there is a growing interest in utilizing surrogate markers as alternative methods for evaluating fat distribution (12). Waist circumference, waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) are anthropometric parameters introduced for abdominal obesity; however, they cannot differentiate visceral from subcutaneous fat (13, 14). Therefore, developing an index that estimates the measure of VAT was necessary.

Lipid accumulation product (LAP) is a classic marker that has shown good performance in predicting visceral fat function, metabolic diseases, and MASLD; however, its role in predicting liver fibrosis remains relatively obscure (15-17). Furthermore, substantial evidence supports that the Visceral Adiposity Index (VAI) has considerable value in predicting metabolic diseases and MASLD; however, there is still controversy regarding the use of VAI as a predictor of liver fibrosis (18-21). Xia et al. (22) developed a Chinese version of the Visceral Adiposity Index (CVAI) to estimate VAT in the Chinese population using age, Body Mass Index (BMI), WC, triglycerides (TG), and HDL-C. Previous studies indicated that CVAI is significantly associated with diabetes, hypertension, and new-onset MI (23-25). Additionally, CVAI plays a significant role in the development of MASLD in healthy Chinese individuals (12). It also demonstrated good diagnostic value for distinguishing MASLD patients from healthy subjects, supporting its use as a screening tool (26).

The role of CVAI in predicting and diagnosing liver steatosis has been investigated in the Chinese population (12, 26). However, it has not been explored in

other Asian populations. Additionally, the value of CVAI in predicting and diagnosing significant fibrosis remains to be elucidated.

2. Objectives

This study aimed to explore the value of CVAI in predicting, grading, and diagnosing hepatic steatosis and fibrosis compared to classic visceral fat markers, such as VAI and LAP.

3. Methods

3.1. Design and Participants

The participants of this cross-sectional study were randomly selected from patients attending a nutrition clinic in the south of Iran (Bandar Abbas city) during 2023. The required sample size for comparing two areas under the receiver operating characteristic curve (AUROC) was calculated to be 274 individuals, with a significance level (α) of 0.05 and a power (β) of 0.2, using GraphPad statistical software. The sample size determination was based on findings by Shen et al. (26), which reported an AUROC of 0.819 for CVAI and 0.772 for VAI, along with a correlation coefficient of 0.85 in both MASLD and healthy groups. Ultimately, 300 subjects over the age of 18 were included, of whom 27 were excluded due to alcohol consumption more than twice a week, any history of infectious or autoimmune hepatitis, congenital hepatic disease, use of anti-epileptics, corticosteroids, methotrexate, tamoxifen, or chemotherapeutic agents, as well as pregnancy or cancer within the last six months. This study was approved by the Ethics Committee of Hormozgan University of Medical Sciences (IR.HUMS.REC.1403.105) and adhered to the 1964 Declaration of Helsinki and its later amendments. All participants provided written informed consent.

3.2. Data Collection

Demographic data, medical history, and physical examination findings were collected via a checklist by an expert nutritionist at the nutrition clinic. Weight was measured to the nearest 0.1 kilograms using a clinical scale (SECA 704; Hamburg, Germany), with participants wearing minimal light clothing and standing barefoot. Height was measured with a standard stadiometer, also without footwear. Body Mass Index was calculated using

the formula: BMI = weight (kg) ÷ height (m²). Waist circumference was measured at the midpoint between the last rib and the iliac crest. Fasting blood sugar (FBS), TG, total cholesterol, LDL-C, HDL-C, aspartate transaminase (AST), and alanine transaminase (ALT) were measured after a 12-hour fast using quantitative diagnostic kits. FibroScan® (Echosens 504, Paris, France) was used to measure the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). The appropriate probe (M or XL) was selected based on the skin-liver capsule distance. The median of ten measurements with IQR/M < 30% was considered a reliable LSM for each patient (27). Compared to liver biopsy, FibroScan demonstrated an AUROC of 0.82, 0.86, and 0.87 for diagnosing F ≥ F₂, F ≥ F₃, and F ≥ F₄, respectively (28).

Abdominal obesity was defined as a WC of 102 cm or more in males and 88 cm or more in females. Hypertriglyceridemia was defined as TG levels of 150 mg/dL or more, or a history of taking lipid-lowering agents. Additionally, males with HDL-C levels of 40 mg/dL or lower, and females with HDL-C levels of 50 mg/dL or lower, were categorized as having decreased HDL-C levels. Diabetes was attributed to participants with FBS levels of 126 mg/dL or higher, or a history of taking antihyperglycemic drugs (29, 30). Values of 238, 260, and 292 dB/m were used for distinguishing S₁, S₂, and S₃, respectively, for steatosis grading. For fibrosis staging, values of 6.2, 7.6, 8.8, and 11.8 kPa were used to determine F₁, F₂, F₃, and F₄, respectively (31). Significant fibrosis was defined as F ≥ F₂ (32).

Lipid accumulation product was calculated based on Kahn's study (15). Visceral Adiposity Index was calculated according to Amato et al.'s study (18). Chinese Visceral Adiposity Index (CVAI) was calculated according to Xia et al.'s formula (22). The formulas are as follows:

- Male: (1) LAP = [WC (cm) - 65] × [TG (mM)]; (2) VAI = [WC (cm)] / (39.68 + (1.88 × BMI) × [TG (mM)] / (1.03) × (1.31) / [HDL (mM)]; (3) CVAI = -267.93 + 0.68 × age + 0.03 × BMI (kg/m²) + 4.00 × WC (cm) + 22.00 × Lg TG (mM) - 16.32 × HDL-C(mM)

- Female: (1) LAP = [WC (cm) - 58] × [TG (mM)]; (2) VAI = [WC (cm)] / (36.58 + (1.89 × BMI) × [TG (mM)] / (0.81) × [(1.52) / [HDL (mM)]]; (3) CVAI = -187.32 + 1.71 × age + 4.23 ×

BMI (Kg/m²) + 1.12 × WC (cm) + 39.76 × Lg TG (mM) - 11.66 × HDL-C (mM)

*Lg' is the symbol for the logarithm with base ten.

SPSS version 27.0 and MedCalc software version 22.009 were used to conduct all analyses. The Kolmogorov-Smirnov test was used to assess the normality of variables. Continuous variables were expressed as mean ± standard deviation (SD), and categorical variables were reported as number and percentage. Independent sample *t*-tests and Mann-Whitney U tests were used to compare the mean of continuous variables between two groups, while the chi-square test was used to compare categorical variables between the groups. Logistic regression was performed to evaluate the predictive value of each visceral fat marker for liver steatosis and significant liver fibrosis. Analysis of variance (ANOVA) was conducted to assess the impact of liver steatosis and fibrosis staging on the values of visceral fat markers. The Welch test was performed if the assumption of equal variances was violated. Tukey and Games-Howell tests were conducted as post hoc tests for classic ANOVA and Welch tests, respectively. The diagnostic accuracy of CVAI and the optimal cut-point value for this index were analyzed by ROC and Youden's Index, respectively. The performance of each visceral marker based on AUROC values is as follows: Fail, 0.5 - 0.6; weak, 0.6 - 0.7; fair, 0.7 - 0.8; good, 0.8 - 0.9; and excellent, 0.9 - 1.0 (33). Statistical analyses used the two-sided test, and a P-value < 0.05 was considered indicative of a significant difference.

4. Results

4.1. Descriptive

In this study, 273 individuals were recruited from patients of a nutrition clinic, with a mean age of 41.74 ± 11.63 years (range: 18 - 73), including 158 (57.9%) males and 115 (42.1%) females. The prevalence of metabolic abnormalities, such as diabetes, hypertriglyceridemia, decreased HDL-C levels, and abdominal obesity, was 66 (24.2%), 142 (52.0%), 142 (52.0%), and 148 (54.2%), respectively. The prevalence of MASLD among participants, by grade, was as follows: Grade I, 37 (13.6%); grade II, 71 (26.0%); grade III, 114 (41.8%). Additionally, the prevalence of liver fibrosis by stage was: Stage I, 44 (16.1%); stage II, 15 (5.5%); stage III, 17 (6.2%); and stage IV, 12

Table 1. Characteristics of Study Participants Across Healthy, Steatosis, and Significant Fibrosis Subjects ^a

Variables	Overall	Steatosis			Fibrosis		P-Value
		Non-steatosis	Steatosis	P-Value	Non-significant	Significant Fibrosis	
Age (y)	41.74 ± 11.63	37.68 ± 12.79	42.66 ± 11.17	0.006	41.81 ± 11.426	41.20 ± 12.86	0.753
Gender				0.269			0.029
Male	158 (57.9)	26 (51.0)	132 (59.5)		126 (55.0)	32 (72.7)	
Female	115 (42.1)	25 (49.0)	90 (40.5)		103 (45.0)	12 (27.3)	
Diabetes	66 (24.2)	11 (21.6)	55 (24.8)	0.630	49 (21.4)	17 (38.6)	0.014
HTG	142 (52.0)	14 (27.5)	128 (57.7)	< 0.001	111 (48.5)	31 (70.5)	0.008
Low HDL-C	142 (52.0)	22 (43.1)	120 (54.1)	0.159	116 (50.7)	26 (59.1)	0.305
Obesity	148 (54.2)	12 (23.5)	136 (61.3)	< 0.001	112 (48.9)	36 (81.8)	< 0.001
BMI (kg/m²)	28.52 ± 4.62	24.71 ± 4.76	29.39 ± 4.12	< 0.001	27.77 ± 4.26	32.40 ± 4.56	< 0.001
WC (cm)	97.12 ± 11.82	85.89 ± 12.20	99.69 ± 10.14	< 0.001	95.11 ± 10.97	107.55 ± 10.75	< 0.001
ALT (IU/L)	49.39 ± 45.03	33.20 ± 43.55	52.80 ± 44.69	< 0.001	42.89 ± 37.56	82.16 ± 62.69	< 0.001
AST (IU/L)	33.91 ± 25.08	25.69 ± 24.86	35.65 ± 24.83	< 0.001	29.88 ± 19.48	54.27 ± 37.57	< 0.001
FBS (mg/dL)	106.72 ± 35.02	100.23 ± 20.50	108.20 ± 37.44	0.150	102.90 ± 23.87	126.28 ± 65.49	0.033
TG (mg/dL)	159.48 ± 105.90	109.78 ± 54.19	170.89 ± 111.53	< 0.001	150.96 ± 91.66	204.61 ± 155.16	0.002
Chol (mg/dL)	188.82 ± 44.47	169.72 ± 35.84	193.21 ± 45.16	< 0.001	186.51 ± 44.58	201.60 ± 42.56	0.023
LDL-C (mg/dL)	111.44 ± 31.61	97.89 ± 30.16	114.55 ± 31.18	0.001	109.42 ± 31.96	121.96 ± 28.13	0.017
HDL-C (mg/dL)	43.25 ± 10.76	46.38 ± 12.20	42.54 ± 10.30	0.022	43.89 ± 10.83	40.33 ± 9.77	0.041
LAP	65.04 ± 53.93	32.73 ± 25.24	72.43 ± 56.03	< 0.001	57.59 ± 38.99	104.24 ± 92.36	< 0.001
VAI	2.779 ± 2.249	1.788 ± 1.246	3.006 ± 2.366	< 0.001	2.583 ± 1.774	3.802 ± 3.763	0.009
CVAI	129.16 ± 51.92	79.58 ± 55.76	140.54 ± 43.78	< 0.001	120.24 ± 48.69	174.71 ± 44.41	< 0.001

Abbreviations: HTG, hypertriglyceridemia; BMI, Body Mass Index; WC, waist circumference; ALT, alanine transaminase; AST, aspartate transaminase; FBS, fasting blood sugar; TG, triglyceride; Chol, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; LAP, lipid accumulation product; VAI, Visceral Adiposity Index; CVAI, Chinese Visceral Adiposity Index.

^a Values are presented as No. (%) or mean ± SD.

(4.4%). The demographic, anthropometric, and paraclinical data are depicted in [Table 1](#).

4.2. Chinese Visceral Adiposity Index in Predicting, Diagnosis, and Grading of Liver Steatosis

Comparison analysis revealed that CVAI values were higher in the liver steatosis group than in the healthy group (140.54 ± 43.78 vs. 79.58 ± 55.76 , $P < 0.001$). The comparison analysis results for VAI and LAP are depicted in [Table 1](#).

In univariate logistic regression, CVAI was significantly associated with liver steatosis (OR = 1.028, CI 95%: 1.019 - 1.037, $P < 0.001$). After adjustment for age, gender, metabolic disorders, and other visceral markers, each unit increase in CVAI increased the odds of liver steatosis by 3.3% (Adj. OR = 1.033, CI 95%: 1.012 - 1.055, $P = 0.002$). The logistic regression results for VAI and LAP are shown in [Table 2](#).

According to ANOVA, the grade of liver steatosis had a significant impact on CVAI [$F(3, 109.29) = 25.695$, $P <$

0.001]. Post hoc analysis indicated that the mean values of CVAI differed significantly between S_3 - S_2 and S_1 - S_0 , while the mean values of CVAI in S_2 - S_1 were roughly equal. The mean and SD of VAI and LAP for each grade of liver steatosis are shown in [Table 3](#).

According to ROC analysis, for $S \geq S_1$, the AUROC of CVAI was 0.800 (95% CI: 0.747 to 0.846) with a cut-point of > 82.62 , sensitivity (SN) of 91.86%, and specificity (SP) of 56.86%. The AUROC, cut points, SN, and SP of other visceral fat markers are depicted in [Figure 1](#).

4.3. Chinese Visceral Adiposity Index, VAI, and Lipid Accumulation Product in Predicting, Diagnosis, and Grading of Liver Fibrosis

Comparison analysis revealed that CVAI values were higher in the significant fibrosis group compared to the non-significant fibrosis group (174.71 ± 44.41 vs. 120.24 ± 48.69 , $P < 0.001$). The comparison results for VAI and LAP are presented in [Table 1](#).

Table 2. Logistic Regression Analysis; The Association of Chinese Visceral Adiposity Index, Visceral Adiposity Index, and Lipid Accumulation Product with Liver Steatosis and Significant Liver Fibrosis

Variables	Steatosis (S ≥ S1)				Significant Fibrosis (F ≥ F2)			
	Univariate Model		Multivariate Model		Univariate Model		Multivariate Model	
	OR (95% CI)	P-Value	OR (95% CI)	P-Value	OR (95% CI)	P-Value	OR (95% CI)	P-Value
Age	1.039 (1.011 - 1.068)	0.007	-	-	0.996(0.968 - 1.024)	0.752	-	-
Gender	0.709 (0.385 - 1.306)	0.270	-	-	0.459 (0.225 - 0.936)	0.032	-	-
Diabetes	1.198 (0.575 - 2.494)	0.630	-	-	2.313(1.167 - 4.584)	0.016	-	-
HTG	3.599 (1.841 - 7.034)	< 0.001	-	-	1.407(0.731 - 2.707)	0.306	-	-
Obesity	5.140 (2.549 - 10.361)	< 0.001	-	-	4.701(2.094 - 10.554)	< 0.001	-	-
Low HDL-C	1.551 (0.839 - 2.865)	0.161	-	-	1.407(0.731 - 2.707)	0.306	-	-
LAP	1.045 (1.029 - 1.062)	< 0.001	-	-	1.016(1.009 - 1.023)	< 0.001	-	-
VAI	1.756 (1.310 - 2.354)	< 0.001	-	-	1.211(1.060 - 1.384)	0.005	-	-
CVAI	1.028 (1.019 - 1.037)	< 0.001	1.033(1.012 - 1.055)	0.002	1.028(1.019 - 1.038)	< 0.001	1.029 (1.011 - 1.047)	0.001

Abbreviations: HTG, hypertriglyceridemia; HDL-C, high-density lipoprotein cholesterol; LAP, lipid accumulation product; VAI, Visceral Adiposity Index; CVAI, Chinese Visceral Adiposity Index.

Table 3. The Analysis of Variance (ANOVA) Results; The Impact of Liver Steatosis and Fibrosis Grading on Chinese Visceral Adiposity Index, Visceral Adiposity Index, and Lipid Accumulation Product^a

Variables	Liver Steatosis							Liver Fibrosis						
	S0	S1	S2	S3	F	P	F0	F1	F2	F3	F4	F	P	
CVAI														
Mean ± SD	79.58 ± 55.76 ^A	118.10 ± 42.12 ^B	131.32 ± 40.32 ^B	153.55 ± 42.44 ^C	25.6	< 0.001	113.92 ± 48.68 ^A	146.69 ± 39.25 ^B	170.16 ± 55.97 ^B	169.57 ± 43.49 ^B	187.68 ± 26.77 ^B	17.2	< 0.001	
VAI														
Mean ± SD	1.788 ± 1.246 ^A	2.536 ± 2.128 ^{A,B}	2.894 ± 1.919 ^B	3.231 ± 2.671 ^B	5.2	0.002	2.520 ± 1.825	2.848 ± 1.534	4.642 ± 5.346	3.200 ± 2.055	3.607 ± 3.359	1.4	0.253	
LAP														
Mean ± SD	32.73 ± 25.24 ^A	49.33 ± 25.38 ^B	66.44 ± 46.54 ^{B,C}	83.89 ± 65.45 ^C	20.8	< 0.001	53.90 ± 38.58 ^A	73.13 ± 37.25 ^B	116.92 ± 132.09 ^{A,B}	90.86 ± 44.93 ^B	107.34 ± 87.75 ^{A,B}	20.8	0.001	

Abbreviations: CVAI, Chinese Visceral Adiposity Index; VAI, Visceral Adiposity Index; LAP, lipid accumulation product.

^a Similar superscript capital letter indicate that there is no significant difference between two levels in post HOC test.

Univariate logistic regression showed that CVAI was significantly associated with significant fibrosis (OR = 1.028, CI 95%: 1.019-1.038, P < 0.001). After adjusting for age, gender, metabolic disorders, and other visceral markers, each unit increase in CVAI raised the odds of significant fibrosis by 2.9% (Adj. OR = 1.029, CI 95%: 1.011 - 1.047, P = 0.001). The logistic regression results for VAI and LAP are shown in [Table 2](#).

According to ANOVA, the stages of liver fibrosis had a significant impact on CVAI [F (4, 267) = 17.239, P < 0.001]. Post hoc analysis indicated no significant difference in mean CVAI values between each two consecutive fibrosis stages. The mean and SD of VAI and LAP for each stage of liver fibrosis are presented in [Table 3](#).

According to ROC analysis, for F ≥ F₂, the AUROC of CVAI was 0.810 (95% CI: 0.759 to 0.855) with a cut-point of >142.42, sensitivity (SN) of 81.82%, and specificity (SP) of 69.30%. The AUROC, cut points, SN, and SP of other visceral fat markers are depicted in [Figure 2](#).

5. Discussion

The study aimed to evaluate the diagnostic value of CVAI for liver steatosis and fibrosis in the Iranian population. Our findings suggested that CVAI, in comparison with VAI or LAP, was a robust predictor of liver steatosis. A cross-sectional study on a Chinese population similarly found that all three visceral indices –CVAI, VAI, and LAP–were independently associated with an increased risk of developing MASLD. However, in




Figure 1. The receiver of operating characteristic (ROC) curves for diagnosing $S \geq S1$. Chinese Visceral Adiposity Index (CVAI): Area under the receiver operating characteristic curve (AUROC) = 0.800 (0.747 to 0.846), cut-point = 82.62, sensitivity (SN) = 91.86%, and specificity (SP) = 56.86%. LAP: Area under the receiver operating characteristic curve = 0.801 (0.749 to 0.847), cut-point = 41.76, SN = 73.42%, and SP = 74.51%. VAI: Area under the receiver operating characteristic curve = 0.715 (0.657 to 0.768), cut-point = 1.57, SN = 74.77%, and SP = 62.75%. WC: Area under the receiver operating characteristic curve: 0.811 (0.760 to 0.856), cut-point = 90, SN = 81.08%, and SP = 68.63%. The AUROC of CVAI was not significantly different from LAP ($P = 0.860$) and WC ($P = 0.264$). However, VAI had significantly lower AUROC than CVAI ($P = 0.047$), WC ($P = 0.031$), and LAP ($P < 0.001$).

prospective analysis, CVAI was shown to be a better predictor of MASLD over a three-year period compared to VAI, LAP, and WC (12). Current findings also indicated that CVAI has good accuracy in diagnosing hepatic steatosis. Nonetheless, CVAI showed no superiority over WC, which is a simple and cost-effective measure for evaluating visceral adiposity. Lipid accumulation product and CVAI had similar levels of accuracy in diagnosing liver steatosis, while VAI showed significantly weaker results than both LAP and CVAI.

Consistent with our findings, Chen et al. (12) observed that CVAI, LAP, and WC had good accuracy in diagnosing MASLD; however, the performance of VAI in differentiating MASLD patients from healthy individuals was only average. Our results also demonstrated that CVAI, unlike VAI and LAP, significantly predicts liver steatosis independently of obesity, dyslipidemia, and diabetes. An analysis of more than nine thousand Chinese subjects found that CVAI is an independent and strong predictor of MASLD in lean adults (26). Moreover, CVAI predicts the likelihood of developing MASLD in diabetic adults, independent of diabetes and other

metabolic factors (34). Overall, CVAI may serve an important role in the screening and risk assessment of MASLD, regardless of age, gender, obesity status, and metabolic diseases.

CVAI was the only visceral adiposity marker that predicted the likelihood of significant fibrosis independently of obesity and other metabolic disorders. However, CVAI is not an efficient marker for differentiating between stages of liver fibrosis. Although Li et al. (35) found that CVAI, VAI, LAP, and WC are associated with higher MASLD activity and have a strong correlation with fibrosis, our findings suggested that only the association with CVAI remained significant after adjusting for confounders.

Accumulating evidence supports the role of VAT in MASLD pathogenesis through mechanisms such as insulin resistance, secretion of pro-inflammatory cytokines and leptin, and the release of high quantities of free fatty acids to the portal vein, which activates toll-like receptor 4 (21, 36-38). While VAI was an excellent surrogate marker for visceral fat volume and function in Caucasians, racial disparities in visceral fat distribution




Figure 2. The receiver of operating characteristic (ROC) curves for diagnosing $F \geq F_2$. Chinese Visceral Adiposity Index (CVAI): Area under the receiver operating characteristic curve (AUROC): 0.810 (0.759 to 0.855), cut-point = 142.42, sensitivity (SN) = 81.82, and specificity (SP) = 69.30. LAP: Area under the receiver operating characteristic curve = 0.745 (0.689 to 0.796), cut-point = 61.82, SN = 77.27, and SP = 65.50. VAI: Area under the receiver operating characteristic curve = 0.625 (0.565 to 0.683), cut-point = 1.53, SN = 88.64, and SP = 34.50. WC: Area under the receiver operating characteristic curve = 0.800 (0.748 to 0.846), cut-point = 104, SN = 70.45, and SP = 83.4. The AUROC of CVAI was not significantly different from WC ($P = 0.579$) and LAP ($P = 0.086$). However, VAI had significantly lower AUROC than CVAI ($P < 0.001$), WC ($P = 0.001$), and LAP ($P < 0.001$).

limit its applicability in Asian populations (18, 39). Consequently, CVAI was developed to estimate visceral fat volume and function specifically in the Chinese population. Chinese Visceral Adiposity Index has shown strong correlations with visceral obesity and the homeostatic model for insulin resistance (HOMA-IR). Additionally, CVAI has been shown to be superior to BMI and WC in assessing risk for metabolic disorders among normal-weight individuals with metabolic disorders and among obese individuals without metabolic diseases (22). These characteristics make CVAI a strong predictor and accurate diagnostic factor for hepatic steatosis and significant fibrosis.

To our knowledge, we are the first authors to investigate the value of CVAI in predicting and diagnosing liver steatosis and significant fibrosis in West Asia. Additionally, the use of elastography in this study enabled us to evaluate the utility of CVAI in grading liver steatosis and staging liver fibrosis, an area that has not been well studied previously. However, due to the cross-sectional nature of this study, a causal

relationship between CVAI and liver steatosis or significant fibrosis cannot be established.

Although our results suggest a potential application of CVAI in MASLD screening, CVAI still requires improved sensitivity and specificity to serve as an ideal marker for MASLD. Other factors beyond visceral adiposity, such as insulin resistance (IR) and systemic inflammation (40), significantly influence the development and progression of MASLD. Including these factors in the CVAI formula may enhance its predictive value and diagnostic power for liver steatosis and fibrosis, as well as that of similar markers.

5.1. Conclusions

In conclusion, our study highlights the superior predictive value of CVAI in diagnosing liver steatosis compared to other visceral adiposity markers, such as VAI and LAP. Notably, the predictive power of CVAI was independent of factors like obesity, dyslipidemia, and diabetes. While CVAI showed good accuracy in detecting hepatic steatosis, it did not surpass the simplicity and cost-effectiveness of WC as a measure of visceral fat.

Additionally, both CVAI and LAP demonstrated comparable accuracy, while VAI showed weaker performance. Furthermore, CVAI was able to predict the likelihood of significant fibrosis independently of metabolic disorders, although it was not effective in distinguishing between different stages of liver fibrosis. Therefore, we propose that CVAI is a valuable tool for screening and risk assessment in MASLD, underscoring the important role of visceral fat in liver health.

Footnotes

Authors' Contribution: A. B., and F. R.: Participated in the concept and design of the study; E. E.: Gathered the data; S. R., and S. H.: Performed data analysis; A. B., and E. E.: Drafted the manuscript; F. R., S. R., and S. H.: Critically reviewed and revised the manuscript. All the authors reviewed the final draft and approved it.

Conflict of Interests Statement: The authors declared that they have no conflict of interest.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after its publication. The data are not publicly available due to the privacy, and ethics. In addition, we believe that the unique insights derived from this dataset can contribute to our own future research endeavors and publications.

Ethical Approval: Current study is carried out under the approval of the ethics committee of Hormozgan University of Medical Science ([IR.HUMS.REC.1403.105](#)), and the 1964 Declaration of Helsinki and its later amendments. All participants filled in written informed consent forms.

Funding/Support: This article was self-funded, and we did not receive any support from any company.

Informed Consent: Informed consent was obtained from all participant.

References

- Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. *J Obes Metab Syndr*. 2023;**32**(3):197-213. [PubMed ID: [37700494](#)]. [PubMed Central ID: [PMC10583766](#)]. <https://doi.org/10.7570/jomes23052>.
- Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest*. 2005;**115**(2):209-18. [PubMed ID: [15690074](#)]. [PubMed Central ID: [PMC546435](#)]. <https://doi.org/10.1172/JCI24282>.
- Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2022;**7**(9):851-61. [PubMed ID: [35798021](#)]. [https://doi.org/10.1016/S2468-1253\(22\)00165-0](https://doi.org/10.1016/S2468-1253(22)00165-0).
- Tabaeian SP, Rezapour A, Azari S, Martini M, Saran M, Behzadifar M, et al. Prevalence of Non-alcoholic Fatty Liver Disease in Iran: A Systematic Review and Meta-analysis. *J Clin Exp Hepatol*. 2024;**14**(1):101209. [PubMed ID: [38076354](#)]. [PubMed Central ID: [PMC10709132](#)]. <https://doi.org/10.1016/j.jceh.2023.06.009>.
- Dietrich CG, Rau M, Geier A. Screening for nonalcoholic fatty liver disease-when, who and how? *World J Gastroenterol*. 2021;**27**(35):5803-21. [PubMed ID: [34629804](#)]. [PubMed Central ID: [PMC8475001](#)]. <https://doi.org/10.3748/wjg.v27.i35.5803>.
- Razmpour F, Nematy M, Belghaisi Naseri M, Dehnavi Z, Ganji A, Vatanparast HA, et al. Which Method is Superior in the Diagnosis of Nonalcoholic Fatty Liver and Steatohepatitis in Children? *Hepatit Month J*. 2017;**17**(10). <https://doi.org/10.5812/hepatmon.13584>.
- Sirli R, Sporea I. Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? *Can J Gastroenterol Hepatol*. 2021;**2021**:6662760. [PubMed ID: [33834008](#)]. [PubMed Central ID: [PMC8018863](#)]. <https://doi.org/10.1155/2021/6662760>.
- Nobarani S, Alaei-Shahmiri F, Aghili R, Malek M, Poustchi H, Lahouti M, et al. Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes. *Dig Dis Sci*. 2022;**67**(4):1389-98. [PubMed ID: [33788095](#)]. <https://doi.org/10.1007/s10620-021-06953-z>.
- Huh Y, Cho YJ, Nam GE. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. *J Obes Metab Syndr*. 2022;**31**(1):17-27. [PubMed ID: [35332111](#)]. [PubMed Central ID: [PMC8987457](#)]. <https://doi.org/10.7570/jomes22021>.
- Nikroo H, Nematy M, Attarzadeh Hosseini SR, Sima HR, Razmpour F. How Does Addition of Regular Aerobic Exercises, Influence the Efficacy of Calorie-Restricted Diet in Patients with Non-Alcoholic Steatohepatitis (NASH)? *Hepatit Month J*. 2017;**17**(5). <https://doi.org/10.5812/hepatmon.45339>.
- Petta S, Amato MC, Di Marco V, Camma C, Pizzolanti G, Barcellona MR, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2012;**35**(2):238-47. [PubMed ID: [22117531](#)]. <https://doi.org/10.1111/j.1365-2036.2011.04929.x>.
- Chen X, Shi F, Xiao J, Huang F, Cheng F, Wang L, et al. Associations Between Abdominal Obesity Indices and Nonalcoholic Fatty Liver Disease: Chinese Visceral Adiposity Index. *Front Endocrinol (Lausanne)*. 2022;**13**:831960. [PubMed ID: [35360076](#)]. [PubMed Central ID: [PMC8960385](#)]. <https://doi.org/10.3389/fendo.2022.831960>.
- Bacopoulou F, Efthymiou V, Landis G, Rentoumis A, Chrousos GP. Waist circumference, waist-to-hip ratio and waist-to-height ratio reference percentiles for abdominal obesity among Greek adolescents. *BMC Pediatr*. 2015;**15**:50. [PubMed ID: [25935716](#)]. [PubMed Central ID: [PMC4446827](#)]. <https://doi.org/10.1186/s12887-015-0366-z>.
- Ghandehari M, Dehnavi Z, Razmpour F, Miryan M, Soleimani D, Parizadeh SM, et al. The Associations of Anthropometric Parameters and Hepatic Steatosis. *J Nutr Fast Health*. 2020;**8**(1):23-7. <https://doi.org/10.22038/jnfh.2019.41464.1208>.

15. Kahn HS. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. *BMC Cardiovasc Disord.* 2005;5:26. [PubMed ID: 16150143]. [PubMed Central ID: PMC1236917]. <https://doi.org/10.1186/1471-2261-5-26>.
16. Mirmiran P, Bahadoran Z, Azizi F. Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients. *Endocrinol Metab (Seoul).* 2014;29(4):443-9. [PubMed ID: 25325262]. [PubMed Central ID: PMC4285040]. <https://doi.org/10.3803/EnM.2014.29.4.443>.
17. Ebrahimi M, Seyedi SA, Nabipoorashrafi SA, Rabizadeh S, Sarzaeim M, Yadegar A, et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. *Lipids Health Dis.* 2023;22(1):41. [PubMed ID: 36922815]. [PubMed Central ID: PMC10015691]. <https://doi.org/10.1186/s12944-023-01802-6>.
18. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. *Diabetes Care.* 2010;33(4):920-2. [PubMed ID: 20067971]. [PubMed Central ID: PMC2845052]. <https://doi.org/10.2337/dc09-1825>.
19. Nusrianto R, Tahapary DL, Soewondo P. Visceral adiposity index as a predictor for type 2 diabetes mellitus in Asian population: A systematic review. *Diabetes Metab Syndr.* 2019;13(2):1231-5. [PubMed ID: 31336469]. <https://doi.org/10.1016/j.dsx.2019.01.056>.
20. Ismaiel A, Jaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis. *Biomed J.* 2021;9(12). [PubMed ID: 34944706]. [PubMed Central ID: PMC8698356]. <https://doi.org/10.3390/biomedicine9121890>.
21. Ercin CN, Dogru T, Genc H, Celebi G, Aslan F, Gurel H, et al. Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease. *Metab Syndr Relat Disord.* 2015;13(7):319-25. [PubMed ID: 26011302]. <https://doi.org/10.1089/met.2015.0018>.
22. Xia MF, Chen Y, Lin HD, Ma H, Li XM, Aleteng Q, et al. A indicator of visceral adipose dysfunction to evaluate metabolic health in adult Chinese. *Sci Rep.* 2016;6:38214. [PubMed ID: 27905531]. [PubMed Central ID: PMC5131270]. <https://doi.org/10.1038/srep38214>.
23. Han M, Qie R, Li Q, Liu L, Huang S, Wu X, et al. Chinese visceral adiposity index, a novel indicator of visceral obesity for assessing the risk of incident hypertension in a prospective cohort study. *Br J Nutr.* 2021;126(4):612-20. [PubMed ID: 33143773]. <https://doi.org/10.1017/S0007114520004298>.
24. Han M, Qin P, Li Q, Qie R, Liu L, Zhao Y, et al. Chinese visceral adiposity index: A reliable indicator of visceral fat function associated with risk of type 2 diabetes. *Diabetes Metab Res Rev.* 2021;37(2). e3370. [PubMed ID: 32562335]. <https://doi.org/10.1002/dmrr.3370>.
25. Cai X, Li N, Hu J, Wen W, Yao X, Zhu Q, et al. Nonlinear Relationship Between Chinese Visceral Adiposity Index and New-Onset Myocardial Infarction in Patients with Hypertension and Obstructive Sleep Apnoea: Insights from a Cohort Study. *J Inflamm Res.* 2022;15:687-700. [PubMed ID: 35140499]. [PubMed Central ID: PMC8819537]. <https://doi.org/10.2147/JIR.S351238>.
26. Shen S, Huang H, Wang J, Tang Z, Shen C, Xu C. Positive Association Between the Chinese Visceral Adiposity Index and Nonalcoholic Fatty Liver Disease in Lean Adults. *Dig Dis Sci.* 2023;68(2):656-64. [PubMed ID: 36512267]. <https://doi.org/10.1007/s10620-022-07787-z>.
27. Gaia S, Carezzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. *J Hepatol.* 2011;54(1):64-71. [PubMed ID: 20932598]. <https://doi.org/10.1016/j.jhep.2010.06.022>.
28. Cassinotto C, Boursier J, de Ledinghen V, Lebigot J, Lapuyade B, Cales P, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. *Hepatol J.* 2016;63(6):1817-27. [PubMed ID: 26659452]. <https://doi.org/10.1002/hep.28394>.
29. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech.* 2009;2(5-6):231-7. [PubMed ID: 19407331]. [PubMed Central ID: PMC2675814]. <https://doi.org/10.1242/dmm.001180>.
30. Richesson RL, Rusincovitch SA, Wixted D, Batch BC, Feinglos MN, Miranda ML, et al. A comparison of phenotype definitions for diabetes mellitus. *J Am Med Inform Assoc.* 2013;20(e2):e319-26. [PubMed ID: 24026307]. [PubMed Central ID: PMC3861928]. <https://doi.org/10.1136/amiajnl-2013-001952>.
31. Razmpour F, Daryabeygi-Khotbehsara R, Soleimani D, Asgharnezhad H, Shamsi A, Bajestani GS, et al. Application of machine learning in predicting non-alcoholic fatty liver disease using anthropometric and body composition indices. *Sci Rep.* 2023;13(1):4942. [PubMed ID: 36973382]. [PubMed Central ID: PMC10043285]. <https://doi.org/10.1038/s41598-023-32129-y>.
32. Mesropyan N, Kupczyk P, Dold L, Weismuller TJ, Sprinkart AM, Madler B, et al. Non-invasive assessment of liver fibrosis in autoimmune hepatitis: Diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction. *Abdom Radiol (NY).* 2021;46(6):2458-66. [PubMed ID: 33078245]. [PubMed Central ID: PMC8205876]. <https://doi.org/10.1007/s00261-020-02822-x>.
33. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. *Biom J.* 2008;50(3):419-30. [PubMed ID: 18435502]. [PubMed Central ID: PMC2515362]. <https://doi.org/10.1002/bimj.200710415>.
34. Tang M, Wei XH, Cao H, Zhen Q, Liu F, Wang YF, et al. Association between Chinese visceral adiposity index and metabolic-associated fatty liver disease in Chinese adults with type 2 diabetes mellitus. *Front Endocrinol (Lausanne).* 2022;13:935980. [PubMed ID: 35979441]. [PubMed Central ID: PMC9376620]. <https://doi.org/10.3389/fendo.2022.935980>.
35. Li R, Liu J, Han P, Shi R, Zhao L, Li J. Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index. *J Gastroenterol Hepatol.* 2023;38(8):1316-24. [PubMed ID: 37102199]. <https://doi.org/10.1111/jgh.16196>.
36. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. *J Gastroenterol.* 2006;41(5):462-9. [PubMed ID: 16799888]. <https://doi.org/10.1007/s00535-006-1790-5>.
37. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Diabetol J.* 2016;59(1):30-43. [PubMed ID: 26407715]. <https://doi.org/10.1007/s00125-015-3769-3>.
38. Hanlon CL, Yuan L. Nonalcoholic Fatty Liver Disease: The Role of Visceral Adipose Tissue. *Clin Liver Dis (Hoboken).* 2022;19(3):106-10. [PubMed ID: 35355841]. [PubMed Central ID: PMC8958250]. <https://doi.org/10.1002/cld.1183>.

39. Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R, et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. *Am J Clin Nutr.* 2012;**96**(4):714-26. [PubMed ID: 22932278]. <https://doi.org/10.3945/ajcn.112.035758>.
40. Ziolkowska S, Binienda A, Jablkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. *Int J Mol Sci.* 2021;**22**(20). [PubMed ID: 34681787]. [PubMed Central ID: PMC8537238]. <https://doi.org/10.3390/ijms222011128>.